Adzymes and uses thereof
OwnerNoubar B. Afeyan, Frank D. Lee +3inventors
InventorsNoubar B. Afeyan, Frank D. Lee, Gordon G. Wong, Ruchira Das Gupta, Brian Baynes
Life of this patent
Estimating the term…
Loading patent…
OwnerNoubar B. Afeyan, Frank D. Lee +3inventors
InventorsNoubar B. Afeyan, Frank D. Lee, Gordon G. Wong, Ruchira Das Gupta, Brian Baynes
Estimating the term…
Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed “adzymes,” comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.
An adzyme for enzymatically altering a substrate, the adzyme comprising:
An adzyme for enzymatically altering a substrate, the adzyme comprising:
An adzyme for enzymatically altering a substrate, the adzyme comprising a polypeptide comprising:
An adzyme for enzymatically altering a substrate, the adzyme comprising:
An adzyme for enzymatically altering a substrate, the adzyme comprising:
An adzyme for enzymatically altering a substrate, the adzyme comprising a polypeptide comprising:
17 The adzyme of claim 10, wherein the Km is at least 20 fold less than that of the catalytic domain alone.
A method of treating an inflammatory of allergic disorder, the method comprising administering a therapeutically effective dose of an adzyme to a human patient in need thereof, wherein the substrate of the adzyme is an inflammatory cytokine.
A cell comprising a first nucleic acid comprising a first coding sequence and a second nucleic acid comprising a second coding sequence, wherein the first coding sequence encodes a first fusion protein comprising an immunoglobulin heavy chain and a catalytic domain, and wherein the second coding sequence encodes a second fusion protein comprising an immunoglobulin heavy chain and a targeting domain.
A method of designing and constructing an effective adzyme, the method comprising:
Dependencies are inferred from the claim text.